Brainomix Showcases Growing Evidence for its Novel AI-Based Imaging Biomarkers in Lung Fibrosis

Key abstracts accepted and presented at ATS included: Key abstracts accepted and presented at ATS included: About Brainomix Brainomix specializes in the creation of AI-powered software solutions to enable precision medicine for better treatment decisions in stroke and lung fibrosis. With origins as a spin-out from the University ofOxford, Brainomix is an expanding commercial-stage company with offices in the UK,Irelandand theUSA, and operations in more than 30 countries...

OXFORD, England, 22/05/2024 (informazione.it - comunicati stampa - salute e benessere)

Key abstracts accepted and presented at ATS included:

About Brainomix

Brainomix specializes in the creation of AI-powered software solutions to enable precision medicine for better treatment decisions in stroke and lung fibrosis. With origins as a spin-out from the University of Oxford, Brainomix is an expanding commercial-stage company with offices in the UK, Ireland and the USA, and operations in more than 30 countries. A private company, backed by leading healthtech investors, Brainomix has innovated award-winning imaging biomarkers and software solutions that have been clinically adopted in hundreds of hospitals worldwide. Its first product, the Brainomix 360 stroke platform, provides clinicians with the most comprehensive stroke imaging solution, driving increased treatment rates and improving functional independence for patients.

To learn more about Brainomix and its technology visit www.brainomix.com, and follow us on Twitter, LinkedIn and Facebook.

Contacts